GENMAB A/S/S (OTCMKTS:GMXAY) Shares Up 4% – Still a Buy?

Shares of GENMAB A/S/S (OTCMKTS:GMXAY) shot up 4% during trading on Wednesday. The stock traded as high as $55.91 and last traded at $55.80. Approximately 5,137,139 shares changed hands during mid-day trading, an increase of 10,480% from the average session volume of 48,553 shares. The stock had previously closed at $53.63.

GENMAB A/S/S Price Performance

The company’s 50-day simple moving average is $39.73 and its 200 day simple moving average is $31.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GENMAB A/S/S stock. Madison Asset Management LLC purchased a new position in shares of GENMAB A/S/S (OTCMKTS:GMXAY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 70,781 shares of the company’s stock, valued at approximately $1,944,000.

About GENMAB A/S/S

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing, and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to develop therapies designed to engage the immune system and target disease-related mechanisms. Genmab’s marketed and partnered products include DARZALEX (daratumumab) for certain blood cancers, EPKINLY (epcoritamab) for certain types of B-cell lymphoma, and Tivdak (tisotumab vedotin) for cervical cancer.